Innovation Pharmaceuticals Inc. (IPIX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -373 Thousand USD | -2.47% |
| 2022 | -364 Thousand USD | 3.7% |
| 2021 | -378 Thousand USD | -189.36% |
| 2020 | 423 Thousand USD | 214.02% |
| 2019 | -371 Thousand USD | 10.17% |
| 2018 | -413 Thousand USD | -1.72% |
| 2017 | -406 Thousand USD | 3.33% |
| 2016 | -420 Thousand USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | -100.0% |
| 2012 | 733.43 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -88 Thousand USD | 11.11% |
| 2023 Q2 | -94 Thousand USD | 0.0% |
| 2023 Q1 | - USD | 100.0% |
| 2023 Q3 | -94 Thousand USD | 0.0% |
| 2023 Q4 | -99 Thousand USD | -5.32% |
| 2023 FY | -373 Thousand USD | -2.47% |
| 2022 Q1 | -95 Thousand USD | 0.0% |
| 2022 FY | -364 Thousand USD | 3.7% |
| 2022 Q4 | -78 Thousand USD | 17.89% |
| 2022 Q3 | -95 Thousand USD | 1.04% |
| 2022 Q2 | -96 Thousand USD | -1.05% |
| 2021 Q2 | - USD | 100.0% |
| 2021 Q3 | -95 Thousand USD | 0.0% |
| 2021 Q4 | -95 Thousand USD | 0.0% |
| 2021 FY | -378 Thousand USD | -189.36% |
| 2021 Q1 | -609 Thousand USD | -2747.83% |
| 2020 FY | 423 Thousand USD | 214.02% |
| 2020 Q2 | 400 Thousand USD | 0.0% |
| 2020 Q1 | 400 Thousand USD | 0.0% |
| 2020 Q3 | - USD | -100.0% |
| 2020 Q4 | 23 Thousand USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 FY | -371 Thousand USD | 10.17% |
| 2019 Q2 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 FY | -413 Thousand USD | -1.72% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 FY | -406 Thousand USD | 3.33% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | -100.0% |
| 2016 Q2 | - USD | 100.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q1 | -50 Thousand USD | 0.0% |
| 2016 FY | -420 Thousand USD | 0.0% |
| 2016 Q4 | 50 Thousand USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | -100.0% |
| 2013 FY | - USD | -100.0% |
| 2013 Q1 | -8650.00 USD | -101.18% |
| 2013 Q2 | -20.41 USD | 99.76% |
| 2013 Q3 | -0.31 USD | 98.48% |
| 2013 Q4 | 29.37 USD | 9573.87% |
| 2012 Q4 | 733.43 Thousand USD | 0.0% |
| 2012 FY | 733.43 Thousand USD | 0.0% |
| 2012 Q2 | - USD | -100.0% |
| 2012 Q1 | 204.14 Thousand USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -15193.153% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 103.186% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -16.742% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.313% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 98.554% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -672.913% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -200.199% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 102.487% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 12124.5% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 103.808% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 667.49% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -992.24% |
| Mesoblast Limited | -35.16 Million USD | 98.939% |
| Marizyme, Inc. | 457.7 Thousand USD | 181.494% |
| Genus plc | 178.7 Million USD | 100.209% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.169% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 699.428% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 190.939% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -3290.909% |
| ContraFect Corporation | -154 Thousand USD | -142.208% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -646.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 585.924% |
| IMV Inc. | -962.29 Thousand USD | 61.239% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 3.742% |
| MultiCell Technologies, Inc. | 49.32 USD | 756385.483% |
| ONE Bio Corp. | 20.12 Million USD | 101.853% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.926% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 862.781% |
| Q BioMed Inc. | -8988.00 USD | -4049.978% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 101.32% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -2318.309% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.841% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 67.326% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 632.857% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -7432.31% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 365.48% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -282.505% |
| GB Sciences, Inc. | -624.00 USD | -59675.641% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -333.58% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.005% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -179226.923% |
| Enzolytics Inc. | 30.7 Thousand USD | 1314.667% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 177.316% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.034% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 27.504% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 160.416% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.091% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -4111.834% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -344.847% |
| Kadimastem Ltd | -630.13 Thousand USD | 40.807% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 137.754% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 103.881% |
| BioStem Technologies, Inc. | 15.42 Million USD | 102.418% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -3051.669% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 311.26% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 311.26% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 127.484% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -1186.207% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 182.881% |
| SYBLEU INC | 11.69 Thousand USD | 3289.124% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 108.095% |
| Bioxytran, Inc. | -8285.00 USD | -4402.112% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Neutra Corp. | 14.33 Thousand USD | 2702.023% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -354.878% |
| PureTech Health plc | -1.6 Million USD | 76.731% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 62.746% |
| IXICO plc | 3.27 Million USD | 111.407% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 46.254% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 79.174% |
| CSL Limited | 7.7 Billion USD | 100.005% |
| Cellectis S.A. | 18 Thousand USD | 2172.222% |